On January 12, 2026, LinkingPharma made a significant announcement regarding its flagship product, Zepuxitinib (LNK01001). The company reported that the drug had yielded promising topline data in a Phase 3 clinical trial aimed at treating moderate-to-severe active rheumatoid arthritis.

This particular study was meticulously designed as a randomized, double-blind, placebo-controlled trial. It encompassed 430 patients who had exhibited a suboptimal response to biologic therapies. These participants were evenly split, in a 1:1 ratio, to receive either 12 mg of Zepuxitinib twice daily or a placebo.

The outcomes of the trial were noteworthy. Zepuxitinib demonstrated a marked superiority over the placebo in achieving the primary efficacy endpoint, which was the ACR20 response rate at Week 24. Furthermore, it also outperformed the placebo in key secondary endpoints, including the ACR50 response rate and the proportion of patients achieving a DAS28-CRP score of ≤ 3.2 (P-value details to be added for statistical significance).